Friends of Cancer Research (Friends) is honored to announce the addition of Roy S. Herbst, MD, PhD, Deputy Director of Yale Cancer Center and Smilow Cancer Hospital and Assistant Dean for Translational Research at Yale School of Medicine, to its Board of Directors.
Dr. Herbst is a nationally recognized expert in lung cancer treatment and research. He is best known for his leadership in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular, the process of linking genetic abnormalities of cancer cells to novel therapies, and his work to bring immunotherapy to the forefront of treatment options for lung cancer.
“We are honored to have Dr. Herbst join our Board of Directors during this exciting time for the organization,” said Friends’ Chair & Founder, Ellen Sigal. “Dr. Herbst’s incredible scientific expertise and dedication to patients will be an invaluable asset for the organization.”
Dr. Herbst has worked for decades as a pioneer of personalized medicine and principal investigator on immunotherapy clinical trials. His research involves identifying tumor biomarkers and bringing novel targeted treatments and immunotherapies to patients.
“Dr. Herbst has been a longtime supporter and key advisor of Friends of Cancer Research. He has been integral to many projects over the years, including the Lung Cancer Master Protocol project and the new generation of Pragmatic Clinical Trials. We welcome him to our board and look forward to his leadership and guidance as we grow the important work of Friends in the future,” Jeff Allen, President and CEO, Friends.
“I am honored to have the opportunity to work more closely together with the leadership of Friends of Cancer Research to help advance their mission to support policy, advocacy, and research for patients with cancer,” said Dr. Herbst.
On behalf of the entire board and leadership at Friends of Cancer Research, we are deeply grateful that Dr. Herbst will be joining our Board of Director’s and advancing our critical work to advance patient care and access.
About Friends of Cancer Research
Friends of Cancer Research (Friends) is working to accelerate policy change, support groundbreaking science, and deliver new therapies to patients quickly and safely. We unite scientists, pharmaceutical companies, and policy makers with shared trust and guide them toward meaningful cooperation. This collaboration among partners from every healthcare sector ultimately drives advances in science, policy, and regulation that speed life-saving treatments to patients. For more information, please visit https://friendsofcancerresearch.org/.